Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AiCME (supported by Bayer) - Navigating new frontiers: Real world evidence's trial in advancing later-line gastrointestinal cancer therapy

Patient selection in the real world: The correct TKI for the correct patient

Date

26 Jun 2024

Session

AiCME (supported by Bayer) - Navigating new frontiers: Real world evidence's trial in advancing later-line gastrointestinal cancer therapy

Topics

Tumour Site

Hepatobiliary Cancers;  Colon and Rectal Cancer

Presenters

Luís Castelo-Branco

Authors

L. Castelo-Branco1, R.D. Kim2, G. Prager3

Author affiliations

  • 1 ESMO - European Society for Medical Oncology, Lugano/CH
  • 2 H. Lee Moffitt Cancer Center University of South Florida, Tampa/US
  • 3 Universitätskliniken der MedUni Wien - AKH Wien, 1090 - Vienna/AT

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.